Results of immunohistochemistry diagnostics of breast cancer in the region of Grodno with consideration of the BRCA1 gene mutation in triple negative cancer

Krylov, A. Yu.; Zubritsky, M. G.; Kurstak, I. A.; Lialikau, S. A.; Basinski, V. A.

doi:10.18786/2072-0505-2017-45-4-302-308

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Наши данные о распространенности мутаций в BRCA1 среди когорты женщин с диагнозом РМЖ на территории Московского региона -3,45% -хорошо согласуются с аналогичными данными, полученными на территории Белгородского (3,2%), Сибирского (3,5%) регионов России, Гродненской области Республики Беларусь (3,8%) [21,25,32]. Несколько меньшие значения в Белгородской области получены, видимо, из-за меньшего спектра анализируемых мутаций.…”

Section: Discussionunclassified

Bayesian assessment of the prevalence of <i>BRCA</i>-associated breast cancer in Moscow

Висковатых

2020

Alʹm. klin. med.

View full text Add to dashboard Cite

Rationale: For many years, breast cancer has been leading in the cancer structure in women, accounting for 21% from the total number of newly diagnosed cases of malignancies in Russia. The literature on the prevalence of the BRCA-associated breast cancer is heterogeneous, which might be related to the specifics of the frequentist analysis. Aim: To assess the prevalence of BRCA-associated breast cancer and the probability of sporadic breast cancer in women of the Moscow region by Bayesian statistics. Materials and methods: The literature search in the E-library.ru database from January 2010 to March 2019 identified 13 original studies and 8 literature reviews with the data on hereditary breast cancer in the territories of the Russian Federation, Republic of Belarus and Ukraine. The assessment of the prevalence of BRCA gene mutation based on the Bayesian statistics and the full probability equation for incompatible events was performed on the data obtained in one study based on molecular genetic tests of 3826 female patients with breast cancer living in the Moscow Region, aged from 22 to 90 years (Russian Scientific Center of Roentgenoradiology). This was the most comprehensive study among those performed in Russia, covering almost all age ranges, with detailed description of the study design, diagnostic methods and the mutations spectrum analyzed. Results: The prevalence of BRCA1-associated breast cancer in Moscow among women is about 0.037%. The general population prevalence of the most frequent mutations of the BRCA1 gene (5382insC, 185delAG, 300T>G, 2080delA, 3819delGTAAA, 4153delA) in the female population in Moscow is about 0.05%, or about 0.1% from the total population. The probability of sporadic breast cancer in the female population of Moscow without any gene dominant mutations associated with breast cancer is about 1%. Conclusion: For the first time, the Bayesian statistics was used to analyze the prevalence of mutations in the BRCA1/2 genes in Russia. The results obtained are in good agreement with similar data for the Belgorod region and the Siberian region of Russian Federation, and the Grodno region of Belarus.

show abstract

Section: Discussionunclassified

Bayesian assessment of the prevalence of <i>BRCA</i>-associated breast cancer in Moscow

Висковатых

2020

Alʹm. klin. med.

View full text Add to dashboard Cite

show abstract

Our Experience of Immunohistochemical Assay in Breast Cancer

Rasulov¹,

Vasikhov²

2020

View full text Add to dashboard Cite

Objective: Analysis of the first experience of immunohistochemical (IHC) diagnostics of breast cancer (BC) in the Republic of Tajikistan for 2018- 2020. Methods: The results of the IHC study of tumor samples obtained by trephine biopsy in 142 patients and the surgical material after radical surgery in 110 patients have been studied. DAKO (Denmark) standard sets used for IHC assay. The staining carried out by manual methodology of the standard protocol provided by the company. The expression of ER and PR, HER2/neu and Ki-67 was determined. Receptive body expression of the ER and PR was evaluated by a point system, by the color intensity and the proportion of stained cells. The degree of HER2/neu expression was determined based on the staining of tumor cell membranes. To determine the threshold value of Ki-67 and subtypes of BC, we used the recommendations of the panel of experts of the St. Gallen Conference on Breast Cancer, proposed in 2013. Results: ER- and PR-positive tumors were found in 54.8% of patients. Negative expression of ER and PR was observed in 38.9% of cases. HER2/neu negative tumor status was found in 68.4%, HER2/neu positive – in 28.8% of cases. Low proliferative activity of Ki-67 was observed in 35.3% of patients, and high proliferative activity – in 64.7% of women. Three times negative BC was found in 23% of patients. Conclusions: High proliferation of steroid hormone receptors, the low proliferation of Ki-67 and absence of HER2/neu are considered favorable prognostic factors. Overexpression of HER2/neu is an unfavorable prognostic sign. High proliferation of Ki-67 is a direct indication for prescribing chemotherapeutic treatment. If technical capabilities are available, the IHC method should be developed in clinics where diagnostic and treatment of BC are conducted. Keywords: Breast cancer, immunohistochemical assay, hormone receptors, steroids, prediction.

show abstract

Results of immunohistochemistry diagnostics of breast cancer in the region of Grodno with consideration of the BRCA1 gene mutation in triple negative cancer

Cited by 2 publications

References 0 publications

Bayesian assessment of the prevalence of <i>BRCA</i>-associated breast cancer in Moscow

Bayesian assessment of the prevalence of <i>BRCA</i>-associated breast cancer in Moscow

Our Experience of Immunohistochemical Assay in Breast Cancer

Contact Info

Product

Resources

About